aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАНateroskleroz-751Research ArticleОБЗОРЫREVIEWSКлетки-супрессоры – основа иммунопатогенеза атеросклерозаThe suppressor cells – the basis of immunopathogenesis of atherosclerosisКозловВ. А.KozlovV. A.

Владимир Александрович Козлов, д-р мед. наук, академик, директор

630099

ул. Ядринцевская, 14

Новосибирск

630099

Yadrintsevskaya str., 14

Novosibirsk

vakoz40@yandex.ruФГБНУ «НИИ фундаментальной и клинической иммунологии»Scientific Research Institute of Fundamental and Clinical Immunology2015170420221123742Copyright © Козлов В.А., 20222022Козлов В.А.Kozlov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/751

   Атеросклероз является сосудистым заболеванием, в процессе формирования которого принимают участие иммунокомпетентные клетки (макрофаги, дендритные клетки, лимфоциты), эндотелиальные и гладкомышечные клеточные элементы во взаимодействии с липопротеинами, обогащенными холестеролом. При этом циркулирующие CD4+ Т-лимфоциты дифференцируются преимущественно в клетки Th1, которые реагируют на специфические антигены, такие как окисленные липопротеины низкой плотности и белки теплового шока (HSP60/65), индуцируя процессы повреждения эндотелия и гладкомышечных клеток. Вопрос о том, будет ли развиваться атеросклероз и любое другое заболевание с иммунопатогенетической основой, зависит от сбалансированного участия в процессе регуляторных клеток с супрессорной активностью, в частности, CD4+CD25+Foxp3+ Treg. Многочисленные данные свидетельствуют о снижении содержания Treg у больных атеросклерозом и уменьшении их супрессорной активности. Все терапевтические воздействия, стимулирующие активность Treg, положительно влияют на течение экспериментального атеросклероза.

   Atherosclerosis is a vascular disease, in the formation of which is attended immunocompetent cells (macrophages, dendritic cells, lymphocytes), endothelial and smooth muscle cell elements in interaction with the lipoprotein enriched with cholesterol. Thus, circulating CD4+ T lymphocytes are differentiated mainly in Th1 cells that respond to specific antigens, such as oxidized LDL and heat shock proteins (HSP60/65) induces the processes of endothelial damage and smooth muscle cells). The question that will or will not develop atherosclerosis depends on balanced participation in the process regulatory cells with suppressor activity, in particular CD4+CD25+Foxp3+ Treg. Numerous data suggest about the reduction of Treg in patients with atherosclerosis and reducing their suppressor activity. All therapeutic effects of stimulating the activity of Treg positively influence the course of experimental atherosclerosis.

атеросклерозиммунологическая толерантностьиммунокомпетентные клетки с супрессорной активностьюimmunopathogenesis of atherosclerosisimmunological toleranceimmunocompetence cells with suppressor activityReferencesZhou X., Nicolleti A., Elhage R., Hansson G. K. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice // Circulation. 2000. Vol. 102. P. 2919–2922.Zhou X., Nicolleti A., Elhage R., Hansson G. K. Transfer of CD4+ T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice // Circulation. 2000. Vol. 102. P. 2919–2922.Getz G. S. Immune function in atherogenesis // J. Lipid Res. 2005. Vol. 46. P. 1–10.Getz G. S. Immune function in atherogenesis // J. Lipid Res. 2005. Vol. 46. P. 1–10.Gratz I. K., Campbell D. J. Organ-specific and memory Treg cells: specificity, development, function, and maintenance // Front. Immunol. 2014. Vol. 5. P. 1–17.Gratz I. K., Campbell D. J. Organ-specific and memory Treg cells: specificity, development, function, and maintenance // Front. Immunol. 2014. Vol. 5. P. 1–17.Wing K., Fehervari Z., Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells // Internat. Immunol. 2006. Vol. 18. P. 991–1000.Wing K., Fehervari Z., Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells // Internat. Immunol. 2006. Vol. 18. P. 991–1000.Nilsson J., Wigren M., Shah P. K. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis // Trends Cardiovacs. Med. 2009. Vol. 19. P. 272–276.Nilsson J., Wigren M., Shah P. K. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis // Trends Cardiovacs. Med. 2009. Vol. 19. P. 272–276.Цырлова И. Г. Влияние клеток «эритропоэтической» селезенки на пролиферацию Т- и В-лимфоцитов / И. Г. Цырлова, Н. В. Кашлакова, В. А. Козлов // Иммунология. – 1986. – № 4. – C. 27–29.Цырлова И. Г. Влияние клеток «эритропоэтической» селезенки на пролиферацию Т- и В-лимфоцитов / И. Г. Цырлова, Н. В. Кашлакова, В. А. Козлов // Иммунология. – 1986. – № 4. – C. 27–29.Jones S., Horwood N., Cope A., Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells // J. Immunol. 2007. Vol. 179. P. 2824–2831.Jones S., Horwood N., Cope A., Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells // J. Immunol. 2007. Vol. 179. P. 2824–2831.Haniffa M. A., wang X.-N., Holtick U., Rae M., Isaacs J. D., Dickinson A. M., Hilkens C. M. U., Collin M. P. Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells // J. Immunol. 2007. Vol. 179. P. 1595–1604.Haniffa M. A., wang X.-N., Holtick U., Rae M., Isaacs J. D., Dickinson A. M., Hilkens C. M. U., Collin M. P. Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells // J. Immunol. 2007. Vol. 179. P. 1595–1604.Fan H., Zhao G, Liu L., Liu F., Gong W., Liu X., Yang L., Wang J., Hou Y. Pre-treatment with IL-1b enhances the efficacy of MSC transplantation in DSS-induced colitis // Cell. & Mol. Immunol. 2012. Vol. 9. P. 473–481Fan H., Zhao G, Liu L., Liu F., Gong W., Liu X., Yang L., Wang J., Hou Y. Pre-treatment with IL-1b enhances the efficacy of MSC transplantation in DSS-induced colitis // Cell. & Mol. Immunol. 2012. Vol. 9. P. 473–481Chan J. L., Tang K. C., Patel A. P., Bonilla L. M., Pierobon N., Ponzo N. M., Rameshwar P. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ // Blood. 2006. Vol. 107. P. 4817–4824.Chan J. L., Tang K. C., Patel A. P., Bonilla L. M., Pierobon N., Ponzo N. M., Rameshwar P. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ // Blood. 2006. Vol. 107. P. 4817–4824.Ait-Oufella H., Salomon B. L., Potteaux S., Robertson A.-K. Gourdy P., Zoll J., Merval R., Esposito B., Cohen J. L., Fisson S., Flavell R. A., Hansson G. K., Klatzmann D., Tedgui A., Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice // Nat. Med. 2006. Vol. 12. P. 178–180.Ait-Oufella H., Salomon B. L., Potteaux S., Robertson A.-K. Gourdy P., Zoll J., Merval R., Esposito B., Cohen J. L., Fisson S., Flavell R. A., Hansson G. K., Klatzmann D., Tedgui A., Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice // Nat. Med. 2006. Vol. 12. P. 178–180.Taleb S., Tedgui A., Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis // J. Int. Med. 2008. Vol. 263. P. 489–499.Taleb S., Tedgui A., Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis // J. Int. Med. 2008. Vol. 263. P. 489–499.Mor A., Planer D., Luboshits G., Afek A., Metzger S., Chajek-Shaul T., Keren G., George J. Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis // Arterioscler. Thomb. Vasс. Biol. 2007. Vol. 27. P. 893–900.Mor A., Planer D., Luboshits G., Afek A., Metzger S., Chajek-Shaul T., Keren G., George J. Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis // Arterioscler. Thomb. Vasс. Biol. 2007. Vol. 27. P. 893–900.McLaren J. E., Ramji D. P. Interferon gamma: a master regulator of atherosclerosis // Cytokine Growth Factor Rev. 2009. Vol. 20, N 2. P. 125–135.McLaren J. E., Ramji D. P. Interferon gamma: a master regulator of atherosclerosis // Cytokine Growth Factor Rev. 2009. Vol. 20, N 2. P. 125–135.Merzrich J. D., Fechner L. H., Zhang X., Johnson B. P., Burlingham W. J., Bradfield C. A. An interaction between kynurenine and the Aryl hydrocarbon receptor can generate regulatory T cells // Immunol. 2010. Vol. 185. P. 3190–3198.Merzrich J. D., Fechner L. H., Zhang X., Johnson B. P., Burlingham W. J., Bradfield C. A. An interaction between kynurenine and the Aryl hydrocarbon receptor can generate regulatory T cells // Immunol. 2010. Vol. 185. P. 3190–3198.De Boer O. J., van der Meer J. J., Teeling P., van der Loos C. M., van der wal A. C. Low numbers of Foxp3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions // PLos ONE. 2007. Vol. 8. e779.De Boer O. J., van der Meer J. J., Teeling P., van der Loos C. M., van der wal A. C. Low numbers of Foxp3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions // PLos ONE. 2007. Vol. 8. e779.Mor A., Luboshits G., Planer D., Keren G., George J. Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes // Eur. Heart J. 2006. Vol. 27. P. 2530–2537.Mor A., Luboshits G., Planer D., Keren G., George J. Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes // Eur. Heart J. 2006. Vol. 27. P. 2530–2537.Han S. F., Liu P., Zhang W., Bu L., Shen M., Li H., Fan Yh., Cheng K., Cheng Hx., Li Cx., Jia Gl. The opposite-direction modulation of CD4+CD25+ Treg and T helper 1 cells in acute coronary syndromes // Clin. Immunol. 2007. Vol. 124. P. 90–99.Han S. F., Liu P., Zhang W., Bu L., Shen M., Li H., Fan Yh., Cheng K., Cheng Hx., Li Cx., Jia Gl. The opposite-direction modulation of CD4+CD25+ Treg and T helper 1 cells in acute coronary syndromes // Clin. Immunol. 2007. Vol. 124. P. 90–99.Gandhi R., Farez M. F., wang Y., Kozoriz D., Quintana F. J., weiner H. L. Cutting Edge: Human Latency-associated Peptide+ T Cells: A Novel Regulatory T Cell Subset // J. Immunol. 2010. Vol. 184. P. 4620–4624.Gandhi R., Farez M. F., wang Y., Kozoriz D., Quintana F. J., weiner H. L. Cutting Edge: Human Latency-associated Peptide+ T Cells: A Novel Regulatory T Cell Subset // J. Immunol. 2010. Vol. 184. P. 4620–4624.Zhu Z. F., Meng K., Zhohg Y. C., Qi L., Mao X. B., Yu K. W., Zhang W., Zhu P. F., Ren Z. P., Wu B. W., Ji Q. W., Wang X., Zeng Q. T. Impaired circulating CD4+LAP+ regulatory T cells in patients with acute coronary syndrome and its mechanistic study // PLos ONE. 2014. Vol. 9 (2). e88775.Zhu Z. F., Meng K., Zhohg Y. C., Qi L., Mao X. B., Yu K. W., Zhang W., Zhu P. F., Ren Z. P., Wu B. W., Ji Q. W., Wang X., Zeng Q. T. Impaired circulating CD4+LAP+ regulatory T cells in patients with acute coronary syndrome and its mechanistic study // PLos ONE. 2014. Vol. 9 (2). e88775.Lin Y.-Z., Lu Z.-H., Lu Z.-D., Huang Y., Shi Y., Liu L., Wang X.-Y., Ji Q.-W. Downregulation of CD4+LAP+ and CD4+CD25+ regulatory T cells in acute coronary syndromes // Med. Inflammation. 2013. Vol. 2013. P. 764082.Lin Y.-Z., Lu Z.-H., Lu Z.-D., Huang Y., Shi Y., Liu L., Wang X.-Y., Ji Q.-W. Downregulation of CD4+LAP+ and CD4+CD25+ regulatory T cells in acute coronary syndromes // Med. Inflammation. 2013. Vol. 2013. P. 764082.Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Stevach E. M., Lipsky P. E. TNF downmodulation the function of human CD4+CD25+hi T-regulatory cells // Blood. 2006. Vol. 108. P. 253–261.Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Stevach E. M., Lipsky P. E. TNF downmodulation the function of human CD4+CD25+hi T-regulatory cells // Blood. 2006. Vol. 108. P. 253–261.Li Q., Wang Y., Chen K., Zhou Q., Wei W., Wang Y., Wang Y. The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome // BBRC. 2010. Vol. 394. P. 836–842.Li Q., Wang Y., Chen K., Zhou Q., Wei W., Wang Y., Wang Y. The role of oxidized low-density lipoprotein in breaking peripheral Th17/Treg balance in patients with acute coronary syndrome // BBRC. 2010. Vol. 394. P. 836–842.Feng J., Zhang Z., Kong W., Liu B., Xu Q., Wang X. Regulatory T cells ameliorate hyperhomocysteinaemiaaccelerated atherosclerosis in apoE-/- mice // Cardiovasc. Res. 2009. Vol. 84. P. 155–163.Feng J., Zhang Z., Kong W., Liu B., Xu Q., Wang X. Regulatory T cells ameliorate hyperhomocysteinaemiaaccelerated atherosclerosis in apoE-/- mice // Cardiovasc. Res. 2009. Vol. 84. P. 155–163.Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells // Science. 2003. Vol. 299. P. 1033–1036.Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells // Science. 2003. Vol. 299. P. 1033–1036.Taleb S., Herbin O., Ait-Oufella H., Verreth W., Gourdy P., Barateau V., Merval R., Esposito B., Clement K., Holvoet P., Tedgui A., Mallat Z. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 2691–2698.Taleb S., Herbin O., Ait-Oufella H., Verreth W., Gourdy P., Barateau V., Merval R., Esposito B., Clement K., Holvoet P., Tedgui A., Mallat Z. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 2691–2698.Zhong Y., Wang X., Ji Q., Mao X., Tang H., Yi G., Meng K., Yang X., Zeng Q. CD4+LAP+ and CD4+CD25+Foxp3+ regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cell response and attenuate atherosclerosis in ApoE-/- mice // J. Clin. Immunol. 2012. Vol. 32. P. 1104–1117.Zhong Y., Wang X., Ji Q., Mao X., Tang H., Yi G., Meng K., Yang X., Zeng Q. CD4+LAP+ and CD4+CD25+Foxp3+ regulatory T cells induced by nasal oxidized low-density lipoprotein suppress effector T cell response and attenuate atherosclerosis in ApoE-/- mice // J. Clin. Immunol. 2012. Vol. 32. P. 1104–1117.Sasaki N., Yamashita T., Takeda M., Shinohara M., Nakajiama K., Tawa H., Usui T., Hirata K.-I. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice // Circulation. 2009. Vol. 120. P. 1996–2005.Sasaki N., Yamashita T., Takeda M., Shinohara M., Nakajiama K., Tawa H., Usui T., Hirata K.-I. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice // Circulation. 2009. Vol. 120. P. 1996–2005.Faria A. M., Weiner H. L. Oral tolerance // Immunol. Rev. 2005. Vol. 206. P. 232–259.Faria A. M., Weiner H. L. Oral tolerance // Immunol. Rev. 2005. Vol. 206. P. 232–259.Dinh T. N., Kyaw T. S., Kanellakis P., To K., Tipping P., Toh B. H., Bobik A., Agrotis A. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+regulatory T cells and attenuates development and progression of atherosclerosis // Circulation. 2012. Vol. 126. P. 1256–1266.Dinh T. N., Kyaw T. S., Kanellakis P., To K., Tipping P., Toh B. H., Bobik A., Agrotis A. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+regulatory T cells and attenuates development and progression of atherosclerosis // Circulation. 2012. Vol. 126. P. 1256–1266.Klingenberg R., Lebens M., Hermansson A., Fredrikson G. N., Strodthoff D., Rudling M., Ketelhuth D. F. L., Gerdes N., Holmgren J., Nilsson J., Hansson G. K. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30. P. 946–952.Klingenberg R., Lebens M., Hermansson A., Fredrikson G. N., Strodthoff D., Rudling M., Ketelhuth D. F. L., Gerdes N., Holmgren J., Nilsson J., Hansson G. K. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30. P. 946–952.Gotsman I., Gupta R., Lichtman A. H. The influence of the regulatory T lymphocytes on atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 2493–2495.Gotsman I., Gupta R., Lichtman A. H. The influence of the regulatory T lymphocytes on atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 2493–2495.Van Brussel I., Schrijvers D. M., van Vre E. A., Bult H. Potential use of dendritic cells for anti-atherosclerotic therapy // Curr. Pharmaceutical Design. 2013. Vol. 19. P. 5873–5882.Van Brussel I., Schrijvers D. M., van Vre E. A., Bult H. Potential use of dendritic cells for anti-atherosclerotic therapy // Curr. Pharmaceutical Design. 2013. Vol. 19. P. 5873–5882.Frodermann V., van Puijvelde G. H. M., Wierts L., Lagraauw H. M., Foks A. C., van Santbrink P. J., Bot I., Kuiper J., de Jager S. C. A. Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a therapy for atherosclerosis // J. Immunol. 2015. Vol. 194. P. 1–11.Frodermann V., van Puijvelde G. H. M., Wierts L., Lagraauw H. M., Foks A. C., van Santbrink P. J., Bot I., Kuiper J., de Jager S. C. A. Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a therapy for atherosclerosis // J. Immunol. 2015. Vol. 194. P. 1–11.Javeed A., Zhang B., Qu Y., Zhang A., Sun C., Zhang L., Liu J., Zeng C., Zhao Y. The significantly enhanced frequency of functional CD4+CD25+Foxp3+T regulatory cells in therapeutic dose aspirin-treated mice // Transplant Immunol. 2009. Vol. 20. P. 253–260.Javeed A., Zhang B., Qu Y., Zhang A., Sun C., Zhang L., Liu J., Zeng C., Zhao Y. The significantly enhanced frequency of functional CD4+CD25+Foxp3+T regulatory cells in therapeutic dose aspirin-treated mice // Transplant Immunol. 2009. Vol. 20. P. 253–260.Takeda M., Yamashita T., Sasaki N., Nakajima K., Kita T., Shinohara M., Ishida T., Hirata K.-I. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30. P. 2495–2503.Takeda M., Yamashita T., Sasaki N., Nakajima K., Kita T., Shinohara M., Ishida T., Hirata K.-I. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30. P. 2495–2503.Perry H. M., Bender T. P., McNamara C.A. B cell subsets in atherosclerosis // Front. Immunol. 2012. Vol. 3. P. 1–11.Perry H. M., Bender T. P., McNamara C.A. B cell subsets in atherosclerosis // Front. Immunol. 2012. Vol. 3. P. 1–11.

The authors declare that there are no conflicts of interest present.